BMO Capital Markets raised the price target for the Constellation Pharmaceuticals Inc. (NASDAQ:CNST) stock from “a Market perform” to “an Outperform”. The rating was released on January 25, 2021. The stock was initiated by JMP Securities, who disclosed in a research note on June 24, 2020, to Mkt Perform and set the price objective to $36. In their research brief published May 07, 2020, H.C. Wainwright analysts reiterated the Constellation Pharmaceuticals Inc. stock to Buy with a price target of $75.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.84 during the last quarter as opposed to a consensus estimate of -$0.79, which indicates the company missed its estimate by -$0.05, which implies that the company surprised the market by -6.30%. It appears that the average earnings per share estimate for the current quarter (ending in Jun 2021) is -$0.89. This is an average of 10 analysts’ earnings, where the high earnings per share estimate is -$0.84 and the low earnings per share estimate is -$0.94.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised 65.86% to close Wednesday’s market session at $33.57, higher as compared to yesterday’s close. The stock price fluctuated between $33.48 and $33.87 throughout the trading session with the volume trading being 28153772 shares, which represented a significant variation when compared to the three months average volume of 440.53K shares. The firm’s stock price fluctuated 72.69% within the last five trades and 60.93% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 32.48% in the last 6 months and 33.43% was added to its value over the previous 3 months. CNST stock is trading at a margin of 65.97%, 53.59% and 32.51% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, CNST deals in the Healthcare domain. The stock is trading -17.80 percent below its 52-week high and 97.47 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -23.77. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Constellation Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $1.62 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 4.25, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Reeve Emma, the Chief Financial Officer at Constellation Pharmaceuticals Inc. (CNST) has sold 6,260 shares of firm on Feb 22 at a price of $37.60 against the total amount of $0.24 million. In another inside trade, Reeve Emma, Chief Financial Officer of Constellation Pharmaceuticals Inc. (NASDAQ:CNST) sold 4,010 shares of the firm on Feb 19 for a total worth of $0.15 million at a price of $37.71. An inside trade which took place on Feb 18, Chief Financial Officer of Constellation Pharmaceuticals Inc. Reeve Emma sold 1,100 shares of firm against total price of $41343.0 at the cost of $37.58 per share.